NASDAQ:ELVN

Enliven Therapeutics (ELVN) Stock Forecast, Price & News

$14.27

+0.38 (+2.74%)

(As of 09/26/2023 ET)

Compare

Today's Range: $13.63
▼
$15.56
50-Day Range: $12.72
▼
$19.23
52-Week Range: $8.48
▼
$25.34

Volume: 483,472 shs
Average Volume: 138,393 shs
Market Capitalization: $587.21 million

P/E Ratio: 4.77
Dividend Yield: N/A
Price Target: $27.00

Enliven Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 89.2% Upside
$27.00 Price Target
Short Interest: Bearish
23.45% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.73
Based on 2 Articles This Week
Insider Trading: Selling Shares
$7.04 M Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($2.12) to ($2.28) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.43 out of 5 stars

Medical Sector

199th out of 964 stocks

Pharmaceutical Preparations Industry

76th out of 445 stocks

3.5

Analyst's Opinion

Consensus Rating
Enliven Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $27.00, Enliven Therapeutics has a forecasted upside of 89.2% from its current price of $14.27.
Amount of Analyst Coverage
Enliven Therapeutics has received no research coverage in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
23.45% of the float of Enliven Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Enliven Therapeutics has a short interest ratio ("days to cover") of 26.3, which indicates bearish sentiment.
Change versus previous month
Short interest in Enliven Therapeutics has recently decreased by 3.40%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Enliven Therapeutics does not currently pay a dividend.
Dividend Growth
Enliven Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ELVN.

3.7

News and Social Media Coverage

News Sentiment
Enliven Therapeutics has a news sentiment score of 1.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Enliven Therapeutics this week, compared to 0 articles on an average week.
MarketBeat Follows
1 people have added Enliven Therapeutics to their MarketBeat watchlist in the last 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Enliven Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,040,000.00 in company stock.
Percentage Held by Insiders
45.80% of the stock of Enliven Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
95.08% of the stock of Enliven Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Enliven Therapeutics are expected to decrease in the coming year, from ($2.12) to ($2.28) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Enliven Therapeutics is 4.77, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 117.25.
Price to Earnings Ratio vs. Sector
The P/E ratio of Enliven Therapeutics is 4.77, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 129.10.
Price to Book Value per Share Ratio
Enliven Therapeutics has a P/B Ratio of 1.04. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Enliven Therapeutics (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.

ELVN Price History

30 days | 90 days | 365 days | Advanced Chart

ELVN Stock News Headlines

August 18, 2023 | seekingalpha.com

Enliven Therapeutics: Preclinical Company With Interesting Value Proposition

August 11, 2023 | finance.yahoo.com

Fairmount Funds Management LLC Acquires New Stake in Kiniksa Pharmaceuticals Ltd

September 26, 2023 | Micro-Cap Stock Trader (Ad)

Unlock the treasure on Mount Olympus with this little-known mining stock.

Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons

August 11, 2023 | finanznachrichten.de

Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

August 10, 2023 | finance.yahoo.com

Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

May 31, 2023 | finance.yahoo.com

Enliven Therapeutics to Present at Two Upcoming Investor Conferences

May 12, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: ProKidney (PROK) and Enliven Therapeutics (ELVN)

May 11, 2023 | finance.yahoo.com

Enliven Therapeutics Highlights Business Achievements and Reports First Quarter 2023 Financial Results

September 26, 2023 | Micro-Cap Stock Trader (Ad)

U.S. drive to onshore battery supply chains could create big winners in lithium

Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons

April 6, 2023 | investing.com

Enliven Therapeutics Inc (ELVN)

March 1, 2023 | wsj.com

Enliven Therapeutics Inc.

March 1, 2023 | nasdaq.com

Enliven Therapeutics, Inc. Common Stock (ELVN)

See More Headlines

Receive ELVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enliven Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ELVN Company Calendar

Last Earnings: 8/10/2023
Today: 9/26/2023
Next Earnings (Estimated): 10/24/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ELVN
CUSIP: N/A
CIK: 1672619
Web: imaratx.com
Phone: 617-927-9989
Fax: N/A
Employees: 37
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $27.00
High Stock Price Forecast: $27.00
Low Stock Price Forecast: $27.00
Forecasted Upside/Downside: +76.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): $2.99
Trailing P/E Ratio: 5.13
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $1.49 million
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -2.16%
Return on Assets: -2.08%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 30.96
Quick Ratio: 30.96

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: $0.39 per share
Price / Cash Flow: 39.20
Book Value: $13.71 per share
Price / Book: 1.12

Miscellaneous

Outstanding Shares: 41,150,000
Free Float: 22,304,000
Market Cap: $630.83 million
Optionable: Not Optionable
Beta: 1.08

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. Samuel S. Kintz M.B.A. (Age 37)
Co-Founder, CEO, Sec. & Director
Comp: $597k

Mr. Benjamin Hohl (Age 34)
CFO & Head of Corp. Devel.
Comp: $488.5k

Dr. Helen Louise Collins M.D. (Age 60)
Chief Medical Officer
Comp: $558k

Dr. Joseph P. Lyssikatos Ph.D. (Age 58)
Co-Founder, Chief Scientific Officer & Directors

Mr. Anish Patel Pharm.D. (Age 43)
Co-Founder & COO

Dr. Galya D. Blachman Esq. (Age 46)
Ph.D., Chief Legal Officer & Head of Bus. Devel.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ELVN Stock - Frequently Asked Questions

Should I buy or sell Enliven Therapeutics stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Enliven Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ELVN shares.
View ELVN analyst ratings or view top-rated stocks.
What is Enliven Therapeutics' stock price forecast for 2023?: 3 Wall Street research analysts have issued 1-year price targets for Enliven Therapeutics' stock. Their ELVN share price forecasts range from $27.00 to $27.00. On average, they anticipate the company's stock price to reach $27.00 in the next year. This suggests a possible upside of 76.1% from the stock's current price.
View analysts price targets for ELVN or view top-rated stocks among Wall Street analysts.
How have ELVN shares performed in 2023?: Enliven Therapeutics' stock was trading at $23.75 at the beginning of 2023. Since then, ELVN stock has decreased by 35.5% and is now trading at $15.33.
View the best growth stocks for 2023 here.
When is Enliven Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, October 24th 2023.
View our ELVN earnings forecast.
How were Enliven Therapeutics' earnings last quarter?: Enliven Therapeutics, Inc. (NASDAQ:ELVN) released its quarterly earnings data on Thursday, August, 10th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by $0.01.

What is Enliven Therapeutics' stock symbol?: Enliven Therapeutics trades on the NASDAQ under the ticker symbol "ELVN."
Who are Enliven Therapeutics' major shareholders?: Enliven Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Commodore Capital LP (5.71%), VR Adviser LLC (5.42%), BlackRock Inc. (3.76%), State Street Corp (1.13%), Geode Capital Management LLC (1.01%) and Northern Trust Corp (0.48%).
View institutional ownership trends.
How do I buy shares of Enliven Therapeutics?: Shares of ELVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Enliven Therapeutics' stock price today?: One share of ELVN stock can currently be purchased for approximately $15.33.
How much money does Enliven Therapeutics make?: Enliven Therapeutics (NASDAQ:ELVN) has a market capitalization of $630.83 million. The company earns $1.49 million in net income (profit) each year or $2.99 on an earnings per share basis.
How can I contact Enliven Therapeutics?: Enliven Therapeutics' mailing address is 309 Beacon Street Suite 300 Office 341, Brookline MA, 02446. The official website for the company is imaratx.com. The company can be reached via phone at 617-927-9989 or via email at ir@imaratx.com.

This page (NASDAQ:ELVN) was last updated on 9/26/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial